26
Mar
2020

Adjusting to Telemedicine: A First-Hand Account

David Shaywitz

One consequence of the present crisis is the urgent embrace of telemedicine, as I recently discussed. Whether the adoption is sustained beyond the crisis period remains to be determined, although use seemed to be increasing overall even before the pandemic hit. 

As more physicians and patients find themselves pressed to adopt telemedicine, I thought it might be helpful to better understand what this transition and experience is like, first-hand. So I asked my brother Jonathan, a psychiatrist in Los Angeles and a relatively early adopter of telemedicine, about his experience.   

Jonathan is an adult psychiatrist, with a focus on anxiety and affective disorders (depression, bipolar, mood disorders), and a particular expertise in psychopharmacology.

Here is what he had to say.

Jonathan Shaywitz, psychiatrist, Los Angeles

Timmerman Report (TR): For starters, help us understand what you typically cover with patients in a (pre-COVID) in-person visit?

Jonathan Shaywitz (JS): Most visits are follow-ups, tend to be extremely targeted, about 15-20 minutes long, and focus on medication management, following up on side-effects, for example.  There’s no physical exam; the questions are generally subjective.

TR: How did you first get involved in telemedicine?

JS: About six years ago, I was medical director at a Southern California hospital system with two large hospitals, half an hour from each other. At the time I joined, the hospital had already installed a telemedicine capability to enable staff at one location to see emergency room (ER) patients and floor [in-patient] consults from the other hospital – you could provide care from one site while physically being in the other. Most importantly, this allowed the ER staff to get in touch with a psychiatrist right away, so it wouldn’t delay the care of patients, and interrupt the flow of ER patients waiting to be seen. In many ER settings, a common hold-up can be waiting for a psychiatrist to come and evaluate a patient.

TR: When you first heard about this set up, were you skeptical? Interested?

JS: I was both interested and skeptical. I was especially skeptical about the technology, because you are really relying on it. I am at my desk at one site, and on the other end, they are wheeling a robot with a video screen with you projected on it. You are counting on the fact that the robot is available and functioning – plus you need someone to appropriately set up the machine. In my experience, this tended to work very well in the ER – basically because there was a single person responsible, and they were very familiar with the technology. Floor consults tended to be more challenging – depending on the floor, you might not have someone around who really knew how to set up the technology.

TR: Do you feel you were able to do as good an exam remotely as if you had seen the patient in person?

JS: I do. There were no procedures involved. Emergency room patients tended to be especially accepting because they were so happy to see a psychiatrist and not have to wait – there was a real sense of time being an issue. The typical evaluation would be for acute depression, often focused on the question of whether the patient was at risk for self-injury.

TR:  Seems like a high stakes evaluation to do remotely – did you feel comfortable, and was it a difficult adjustment?

JS: I did feel comfortable, and it didn’t seem like a difficult adjustment, at least not in this setting, because the exam is so targeted and focused, and the patient is in a well-controlled environment. Floor consults were a little more challenging, both because of the technology issues I mentioned earlier, and also because the consults could be more vague, and less focused.

TR: Did you feel that on these floor consults, you were able to be as effective when you used the robot?

JS: It can be a little more difficult; when you consult in person, you often are dependent on collateral information, such at what you might learn from a family member who’s nearby or waiting outside. It’s harder to get some of that information when you’re using the robot.

TR: You went on to use telemedicine extensively in out-patient psychiatry; what was that experience like?

JS: In the outpatient setting, you can’t control the environment, in contrast to the hospital ER and floor consults. You’re at the whim of the patients, and often they take it a little less seriously. When patients come to the doctor’s office, they tend to be more focused, and in the moment. The big advantage of telemedicine, of course, is the convenience, but this can also mean a patient is multitasking, or not speaking from a conducive location. Many telemedicine doctors talk about this challenge. I’ve had patients who would be talking with their friends, watching television, or just in a crowded place. This is a problem not only in terms of security and privacy, of course, but also, at least as importantly, because the patients tend to be distracted by the environment. Telemedicine doctors try to manage this by setting limits and having boundaries.

TR: So given all this, what’s your view of telemedicine? 

JS: I encourage it. Even with all the challenges, it is still better than people not being able to make it to appointments. The overall quality of care you can deliver because of the continuity more than makes up for the occasional challenges of a session.

The overall quality of care you can deliver because of the continuity more than makes up for the occasional challenges of a session

TR: How do you have to adjust your style for telemedicine?

JS:  You need to be more structured with patients. You also have to set limits.

TR: For your outpatient interactions, was technology an issue? 

JS: No, not at all – we used a HIPAA-compliant app, which worked extremely well.

TR: What about reimbursement – it sounds like that can be a problem for many?

JS: When I first started, some insurance companies would only reimburse for face to face encounters – but that’s really improved now. 

TR: And is there a requirement for an initial meeting face to face? 

JS: Initially that was true, but it seems to have gotten relaxed over time for many payors.  Often, it’s the physician that wants the initial meeting in person.

TR: Finally, what do you see as the future of telemedicine?

JS: Even before COVID-19, telemedicine was skyrocketing. It is the future, especially in areas like psychiatry. Because it’s not procedural, the major factor is convenience – time and geography – and telemedicine allows patients to fit in appointments much more easily. The key needs are checking in and continuity, and telemedicine affords this.

26
Mar
2020

The Coronavirus Tsunami, Lyell’s $492M Megaround & Some Deals You Missed

Luke Timmerman, founder & editor, Timmerman Report

When a story moves with exponential speed and deadly force, it’s hard for a human being to keep up.

Hard for you, and hard for me.

My approach these past few weeks has been to work with purpose and passion on this story that touches all of humanity. The plan has been to seek out diverse voices with fresh perspectives on the pandemic, recruit them to write for TR, and aggressively edit and publish their work in addition to mine. All of the pandemic coverage is being made completely free (no ads, no subscription required), so you can share this quality coverage with family, friends, and colleagues. I am grateful to see so many of you appreciate it.

Human life is on the line. People need quality information to make the best decisions in their daily lives. Journalism always has a public service duty, but it’s never more important than times like now. That’s why everything on Timmerman Report related to the pandemic is being made free, so you can share it with your loved ones, friends, and colleagues who need quality news and information, as opposed to the propaganda and entertainment that tends to drive too much public discourse.

My hope is that in the weeks ahead, you can count on TR to keep things in perspective, while you do what you have to do to keep your families safe and your companies operating under stress. Expect a mix of informative, data-rich voices, and fresh perspectives that can help guide us all through the crisis. Knowing the emotional strain the pandemic puts on people, expect these pages to also shine a light on writers who tap into the human dimension which is too often overlooked in the business world. You may even get a dose of humor once in a while, like yesterday’s piece by Lisa Suennen.

As a Timmerman Report subscriber, I want you know my inbox is open to you. I’m listening.

If you have suggestions of people and ideas that I should consider, let me know. luke@timmermanreport.com.

Now on to your regularly weekly Frontpoints.

The Table That Has Me Most Worried

The US healthcare system apparently relies on threadbare-thin just-in-time inventory stocking for essentials, like personal protective equipment, to a far greater extent than most of us imagined. The shortages of PPE this early in the pandemic response, along with woefully inadequate diagnostic testing in too many parts of the country, are deeply troubling at this late date of Mar. 26. Why in the world didn’t we scale up manufacturing starting Feb. 1, when the alarm bells were clear from China. Or how about Mar. 1, when it was abundantly clear we had uncontained community transmission in the Seattle area for the preceding six weeks? The federal government’s denial, incompetence, short-term thinking, and outright dangerous lies  — it’s a nightmare beyond even my darkest fears from the past few years.

I’ve spoken with doctors and nurses. The fear in their voices is palpable. They know this virus is highly contagious. They know it sends about 15-20 percent of people who get it to the hospital. Many patients need ventilators which we don’t have. Where in the world are all these patients going to go to get the adequate first-world care they need to survive?

How far do we have to go to catch up? Forgive the crude table below, which includes data compiled by OECD on hospital beds per 1000 people, through 2017. You have to scroll a long way down to find the United States.

The United States ranks No. 32 in the world, with fewer than 3 hospital beds per 1,000 people (below countries like Italy and Spain, which have been overwhelmed).

 

Beds are something of a proxy for hospital capacity. Now, you might say, beds can be obtained and rolled out in surge hospitals like the Javits Center in New York. Sure. But even if beds are installed, who will tend to the patients? Anyone familiar with unionization drives for nurses over the past 10 years knows that they are being run ragged and overscheduled,  even in normal times. We don’t have a deep bench of reserves to call up. If these frontline workers start getting sick, we simply won’t have enough skilled people to provide care. (See table below from Kaiser Family Foundation, based on OECD data).

 

Dashboards to Help You Keep Up (Which You Probably Already Have)

The New York Times has a nice visualization of the US map, along with new cases, and deaths, reported on a daily basis. (NYT Latest Map and Case Count). The NYT, given its resources, should lead the US media. It has been simply superb in its overall team coverage.  

Johns Hopkins University is a go-to source for worldwide case counts, and deaths, updated in real-time. Sadly, you can see the US moving up to the top of the list, surpassing China as of Mar. 26, in terms of total number of confirmed cases. (Johns Hopkins dashboard).

Covidactnow.org is an excellent resource that provides colorful state-by-state projections of what various scenarios look like, with aggressive community mitigation and without. (H/t to TR subscriber Steve Dickman of CBT Advisors for sharing).

Covidly.com. A simple display. US is now No. 1 in the world in terms of confirmed cases.

Sad, but Predictable Fallout

Eli Lilly announced something that should have been pretty easy to anticipate a couple weeks ago. Clinical trial activity is being curtailed during the COVID19 pandemic. New trials in the queue aren’t being started. Enrollment of new patients in existing trials, are being paused. Existing patients in trials who need to stay on protocol as part of their care plan, will maintain continuity on study. I’d watch for more shoes like this to drop in coming weeks.

Silver-lining Department

Scientists, doctors and nurses will be the new heroes in our society in the 2020s and beyond.

A few highlights from the world of science:

Seattle is a few weeks ahead of the rest of country in the coronavirus outbreak. The Seattle Flu Study, which was set up as a $20 million project to gather samples from people suffering flu-like symptoms in the community to better understand that virus, has been nimbly, and heroically, repurposed to evaluate the community spread of SARS-CoV-2. These scientists from the University of Washington and Fred Hutch have not only provided a crucial set of data-driven warnings to scientists around the US, they’ve turned virology labs into a high-volume testing center when the federal government failed to keep up with a virus that spreads with exponential speed. Read about the Seattle team’s new research plan here.

A brute force team of scientists led by the famous drug hunter Kevan Shokat at UCSF published what you’d have to call a tour de force of a preprint on BioRxiv. They described their work probing for an Achilles heel in SARS-CoV-2. They found “332 high confidence SARS-CoV-2-human protein-protein interactions (PPIs). Among these, we identify 66 druggable human proteins or host factors targeted by 69 existing FDA-approved drugs, drugs in clinical trials and/or preclinical compounds, that we are currently evaluating for efficacy in live SARS-CoV-2 infection assays.” Talk about working with purpose and passion. Who knows where this will lead, but holy mackerel. Read the preprint yourself here.

Scientists in China, alongside US peers, are looking at lightning speed for broadly neutralizing antibodies against SARS-CoV-2. Chinese scientists reported Mar. 25 on an almost incredible 206 broadly neutralizing antibodies against the receptor-binding domain on the virus. Antibodies can provide exquisite specificity to a target. The Chinese team reported surprisingly little cross-reactivity with SARS and MERS. But one challenge with antibodies is they are difficult to scale up for all-out mass production quickly. If these go anywhere, antibodies in beginning small batches could be an especially important tool for treatment of patients in severe distress, and potentially for prophylaxis of healthcare workers on the front line. That would be an interim step before we get a cheap, effective vaccine that can be given worldwide.

Disease modelers at Imperial College London rocked the world with their original report on Mar. 16 that as many as 2.2 million people in the US could die from COVID19 in a worst-case scenario. Some skeptics wondered if this was alarmism, given the thin gruel of actual hard testing data that the modelers had to work with in order to make their projections, including the crucially-important Case Fatality Rate. Data on hospitalization rates, similarly, is hard to pin down with sweeping, and accurate, testing data. Even so, a lot more data has come in worldwide in the last 10 days. Now the Imperial College London team is out with a new report on Mar. 26. The updated report expects 7 billion infections and 40 million deaths worldwide this year with no interventions. Mitigation strategies could cut the death toll in half, but would still result in overwhelmed healthcare systems. (Full Mar. 26 report here).

COVID-19 Reading from Around the Web

 

TR Coverage of the Pandemic (Free & shareable with friends, family & colleagues)

Tweetworthy

Craig Spencer is a physician in New York City. Healthcare workers there are in serious trouble. The wave of COVID19 patients is coming to parts of the US, too.

Read this tweet, which sums up this disastrous state of affairs, and boils with frustration.

In Other News…

Deals

Redwood City, Calif.-based Codexis formed a partnership with Takeda to make novel enzyme sequences for use in gene therapy preclinical development. Terms not disclosed.

South San Francisco-based CytomX Therapeutics pocketed an $80 million upfront payment from Astellas to co-develop bispecific antibody treatments for cancer. 

Pfizer partnered with Germany-based BioNTech to work on an mRNA-based Covid-19 vaccine. Plans to work out financing terms will get worked out later, given the urgent need. Cambridge, Mass.-based Moderna staked out a lead in the category, dosing the first patient in a healthy volunteers trial in Seattle, the epicenter of outbreak in the US.

Data That Mattered

Genentech and AbbVie reported that venetoclax (Venclexta) improved overall survival time, in combo with azacitadine, compared with the standard chemo, in a Phase III trial of patients with acute myeloid leukemia. Details coming at a future medical meeting (whenever they might be held again).

Financings

South San Francisco-based Lyell Immunopharma raised $492 million in a Series C equity financing that included 10 investors, according to a regulatory filing with the SEC. The company didn’t issue a press release on the financing, but Bob Nelsen of Arch Venture Partners confirmed to me that Arch participated, and has plans to continue with three large financings in coming weeks, despite the pandemic. Lyell is led by CEO Rick Klausner, a former director of the National Cancer Institute and a co-founder of Juno Therapeutics.

South San Francisco-based CERo Therapeutics raised $40 million in a Series A financing. The company is working on engineered T cells for solid tumors. Arch Venture Partners participated. (See TR coverage on T cells for solid tumors, March 2020). CERo also said it struck a partnership with Lyell Immunopharma.

San Diego-based Design Therapeutics raised $45 million in a Series A financing led by SR One. The plan is to work on nucleotide repeat disorders, starting with Friedreich’s ataxia.

Menlo Park, Calif.-based ReCode Therapeutics secured an $80 million Series A financing, co-led by OrbiMed Advisors and Colt Ventures. The company pools some assets for mRNA and tRNA therapeutic development for lung diseases, starting with primary ciliary dyskinesia and cystic fibrosis.

Emeryville, Calif.-based Eureka Therapeutics raised a $45 million Series E financing to advance its cancer treatment programs. Lyell Immunopharma led.

24
Mar
2020

Doctor, Mother, CEO: Balancing Competing Needs, and Opting for the Front Lines

Amanda Banks Christini, MD; CEO, Blackfynn

Yesterday I woke up on an island.

I am temporarily – but purposefully — isolating myself and my two children, ages 10 and 12, in a familiar place that carries with it a slower rhythm from a different time. It’s our second home.

It also happens that, on the first day of spring, there are still no cases of suspected or confirmed COVID-19 on this island. Talk about isolation.  

A week ago, I left Philadelphia to come here for the safety of my family.

But I didn’t leave our communities, or our world, behind. I’ve decided to come back, and put my medical training to work on the front lines during this time of urgent need.

We are all struggling with, distracted by, this new reality that has been thrust upon us by the completely predictable intersection of a rapidly transmissible, emerging infectious disease and a fatally neglected public health infrastructure.

Our current administration is adding fuel to this fire through characteristic and striking ignorance. The administration’s actions — and inaction — will have profound long-term effects on our fragile healthcare system and on our economy. But while the temptation to place all the blame at the feet of elected officials is strong, we are in this situation because of many decades of broken policies and misplaced investment.

I am angry and frustrated. But I don’t have time for this now, because I am consumed by the balance between being a CEO of a company with 36 employees, a mother, a daughter, a sister, a friend, and, a practicing internal medicine physician who also works as a hospitalist in Philadelphia to care for acutely ill inpatients.

I am profoundly wrestling with the obligations of these roles, which, in this new reality, can be both fully aligned and simultaneously in stark conflict.

I have a fiduciary duty, as CEO, to not take undue risks as a “key person” at my company. But the healthcare system will collapse under the weight of this pandemic if healthcare workers don’t step up. And they are stepping up in droves, despite the lack of supplies. My employees need decisive leadership. They also seek my medical advice at a time when the mixed messages of state and federal officials, combined with certain media outlets with irresponsible tendencies and partisan biases, is deafening. It’s hard to know what to believe. I am balancing my passionate dedication to patients with a fierce instinct to protect my children.

I jumped on the front lines in 2014 as a first responder against Ebola and was a (pregnant) medical resident taking care of patients with H1N1 flu in 2009. I will not sit on the sidelines and watch my colleagues fight this battle.

In the end, despite the risk I know it will pose to me and possibly my kids, I will have to leave the temporary isolation of my island retreat. I will have to make arrangements for child care, and then go to the front lines. I need to help care for not just patients with COVID-19 infection, but also for the many patients with heart failure exacerbations, complications of uncontrolled diabetes and hypertension, renal disease, heart attacks and strokes who are admitted in greater numbers because their routine clinic visits have been cancelled to make way for the surge of pandemic victims in dire need. We are going to see a chain reaction of more sickness in these patients, because they won’t get adequate telemedicine consults. That’s because this country has never prioritized, nor authorized reimbursement for, telemedicine services.

As CEO I made the decision, like many others, to make working remotely mandatory. I am trying to keep a company of now fully remote workers engaged, productive, motivated and safe – a company that I co-founded, that I lead, to which I am passionately dedicated. The employees are people to whom I am deeply connected and feel a tremendous responsibility. In a world where the financial markets went from soaring to reactive, trepidatious and emotional, I am also trying to steer our company through an unprecedented time, at a moment when we were, and are, poised to do great things to impact patients.

We all have our version of this struggle. We are all some combination of parents, kids, friends, leaders, colleagues. We will redefine what social engagement means. We will find new ways to fulfill our need for community. We will get sick, and help others get well. Realistically, some of us will die.

But, as a community, a nation, and a world, we will get through this. I can only hope that when we do, we indeed come through to the other side stronger.

I implore everyone to learn from this unprecedented moment in history; in a nation so fundamentally short-sighted and focused on the value of the individual, can we become a country with a longer view? One informed by science, epidemiology and the value of basic principles of public health? The decision is ours: as a world, as a nation, as a community, but also as individuals.

I do not have the answers. I can – we all can – ask questions. Today, I am back in Philadelphia preparing to go on service on nights and weekends to treat patients. This is my contribution.

We must all contribute in our own way: Don’t hide. Don’t let fear paralyze you: find facts and resist the noise. Be kind to each other. Find empathy. Resist hoarding food and supplies — especially masks that medical workers and people on the front lines desperately need and are in dangerously short supply. Build virtual communities. Support a friend or coworker or family member who is alone and at risk.

And vote. Especially, vote.

Together we can use this remarkable moment to catalyze the change our nation and our world so desperately needs. The time is now.

What will you do?

24
Mar
2020

Digital Tools in Clinical Trials Find Opportunity During Pandemic

David Shaywitz

The current crisis represents a potentially defining moment for at least some health technologies and technology-enabled services. 

Telehealth, as discussed in my last column, is one conspicuous example, and the jury is still out. The potential benefit seems especially striking at a time when so many Americans are being told to stay at home, yet there are also serious concerns, both short-term (can existing telehealth capabilities adapt to exploding demand?), and longer-term (including not only a thicket of regulatory and reimbursement hurdles, but also challenges around data governance and trust).

Nevertheless, as Dr. Joseph Kvedar, VP of Connected Health at Partners HealthCare puts it, “telehealth is clearly making the case for how technology should be used to imagine how care and services are delivered.  I believe that there will be no turning back.”

The corresponding example from the pharma world might be the use of technology to enable remote trials. It’s an urgent consideration in light of the pandemic, which is having a predictably negative impact on clinical trials. In the last 24 hours, Lilly announced it would “delay most new study starts and pause enrollment in most ongoing studies,” while “continuing ongoing clinical trials for patients who are already enrolled.”  Meanwhile, the New York Times reports BMS has told researchers “it will put off beginning new clinical trials for at least three weeks,” “will not initiate any new sites for clinical trials until April 13” (or later), and said “studies involving healthy volunteers should be paused if they are at a natural break point until at least April 13.”

Clinical trials, like much of clinical medicine, have historically focused around global networks of brick-and-mortar centers. These centers can be stand-alone facilities, which are typical for early phase, highly monitored studies. They can also exist in large medical centers with physicians who have agreed to participate in the study. That model is quite common for larger, mid- and late-phase studies.

While operating in a site-focused fashion enables a relatively high degree of process control, it also means that studies are generally limited to subjects who can show up to a single location, often repeatedly over days, weeks, and typically months. The convenience challenge is often cited as a major reason why participation in clinical trials is so abysmally low.

This matters for many reasons: a key hurdle for clinical studies is it often really difficult to find enough patients to study, a persistent challenge which adds significantly to the length and cost of trials.It also means that many potential subjects never have the opportunity to participate because they are not located near a trial site and/or the time and travel commitments are prohibitive.

Estimates vary for just how small the percentage of eligible patients who participate in trials is. Some suggest the figure is as low as 2%; a recent study led by Joseph Unger of the Fred Hutchinson Cancer Research Center and focused on cancer patients puts the number at 8%. Foremost among the factors cited for low participation by Unger and his co-authors is that “a trial may not be available where the patient is being treated.” As they point out, “Having to travel to participate in a trial can be an overwhelming burden to patients.” 

Driven by these widely recognized needs, there has been profound interest in finding ways to increase the reach of clinical trials, which often involve the idea of the trial going to the patient, rather than the patient going to the trial. This was the driving force for Novartis to ink a high-profile deal with the remote trial company Science37 in 2018, a pact aiming to deliver 10 studies in three years (our TechTonics episode with Science37 co-founder and former-CEO Noah Craft, who stepped down in 2019, is here).

As the Novartis press release put it, “Decentralized, or virtual, trials harness digital technology to allow some or all aspects of a clinical trial to be carried out at a participant’s home or local physician’s office, rather than at a central trial site such as a large hospital…”

Improving the diversity of participants is another attraction of virtual approaches. As a Novartis executive says in the same statement, “Remote participation in research has the benefit of improving the breadth of participation from wider community and socio-economic backgrounds, while also allowing us to gather more meaningful real-world evidence in our clinical trials.”

In theory, a company that had an established, decentralized trial capability might be more robust to site-focused challenges like those associated with the pandemic. Certainly, the FDA’s recent guidance makes clear it is receptive, under the conditions of the pandemic, to remote approaches as supportive of participant safety. 

The guidance document specifically encourages sponsors to consider “alternative methods for safety assessments” such as “phone contact, virtual visit, alternative location for assessment,” and presses sponsors to “determine if in-person visits are necessary to fully assure the safety of trial participants.” 

The Agency goes on to note that depending on the circumstances, some “investigational products that are normally administered in a health care setting” might be given some other way (“e.g. home nursing or alternative sites by trained by non-study personnel”). The Agency even suggested the possibility of “the use of virtual assessments” for efficacy evaluations. Collectively, the document at a minimum highlights the potential of a remote clinical trial capability, which would seem useful in the context of this crisis. 

My best guess, however, is that remote trial monitoring is still such an emerging capability that few, if any, pharmas have it available as a ready substitute for in-person visits; this may not even be appropriate for many study protocols. Some experts such as Andrew Matzkin, a partner at the consultancy Health Advances, believe that decentralized clinical trials may be a promising concept that could work technologically, but still need to provide more evidence, demonstrate real world usability, establish credibility, and  describe a reliable path to commercial scale before they’re likely to gain general acceptance.

Perhaps for a few very high priority trials that are already underway, pharmas are likely to do every possible thing they can to keep these studies advancing. Pharma companies will try to use remote capabilities and deployed specialists to perform the necessary evaluations, assessments, and (where required) dosing. Especially at a time when health systems and healthcare workers are already so overwhelmed, any success from this approach is likely to be extremely limited.

At times of crisis, it’s often said that the startups that benefit the most aren’t those that are formed in the heat of the moment to address the emergent needs, but rather those that were created years back, and are poised, for lack of a more tasteful term, to take advantage of the moment. 

Two startups in this space are Evidation Health and Koneksa Health, which both offer flavors of what might be called “digital tool enablement as a service.” While neither seem positioned to save pharma from the trial continuity crisis, the value of their capabilities is likely to be evaluated and recognized at this moment.

Evidation Health, led by Deb Kilpatrick (her TechTonics episode here), is perhaps best known in recent days for its partnership in the “Heartline” 150,000 person study – “a big deal of digital health” according to CNBC’s Chrissy Farr – recently launched by J&J and Apple. Heartline’s website says Evidation “provides the technology and study operations that enable the Heartline app and study experience for participants.” Their role, Kilpatrick says, is as the “software-based virtual site,” explaining that Evidation’s research platform enables a contemporary, decentralized research experience for older adults mediated entirely through the iPhone while collecting and processing their (explicitly consented) research data.

Evidation believes its secret sauce is gleaning insight from the data generated by these digital tools – information the company refers to as “person-generated health data, or PGHD), a distinctly non-trivial task accomplished by the data science team build by co-founder Luca Foschini. Evidation’s approach has been used in studies of the flu, as well in a recently-launched longitudinal program seeking to better understand the perceptions, experience, and health of Americans in response to the pandemic; using its already-deployed patient engagement app called Achievement, the company hopes to integrate surveys and digital measurements from users who opt-in; as of March 18, over 100,000 people apparently had.

If Evidation’s focus is obtaining meaningful clinical insights by analyzing what it would describe as high-quality, person-generated health data from consumer devices and engagement apps, Koneksa Health is especially focused on the validation of remote measures for use in traditional clinical trials, and supporting pharma stakeholders who make go/no-go decisions, as well as the regulatory authorities who must accept digital measures in place of, or in addition to, the current gold standard. (My simple-minded dichotomy sees Koneksa focused on pre-approval trials, and Evidation capturing value from post-approval studies and other research; in reality, the capabilities of these two companies presumably overlap).

Koneksa’s focus, says founder and CEO Chris Benko (his TechTonics episode here) is the use of patient-focused digital biomarkers (e.g. remote, device and app based measures of pulmonary function, activity, sleep, vital and hefty signals) to support development of novel therapeutics.”

Benko’s view is that the current crisis, and the FDA’s response, “will require technology tools already designed as fit-for-purpose clinical trial tools,” adding “Koneksa has been deploying tools like this into clinical trials since we launched in 2015.”

Bottom Line: While no company seems poised to save pharma from the clinical trial interruption the pandemic has necessitated, the urgent search for partners with digital capabilities may accelerate the growth of startups like Koneksa and Evidation who are progressively establishing themselves in this nascent and promising space.

23
Mar
2020

New Drugs at Low Prices: Alexis Borisy and Melanie Nallicheri of EQRx on The Long Run

Today’s guests on The Long Run are Alexis Borisy and Melanie Nallicheri.

Alexis Borisy, chairman and CEO, EQRx

Alexis is the chairman and CEO of EQRx, and Melanie is the president and chief operating officer.

EQRx is a startup in Cambridge, Massachusetts. It aspires to develop new medicines for serious diseases like cancer. That’s nothing unusual.

What is unusual is that EQRx is seeking to create a company that makes a profit, but does so by churning out many new drugs so it can get by without resorting to the unjustifiable price increases, or outright price-gouging, that has poisoned the reservoir of public trust in the biopharmaceutical industry.

Essentially, it wants to develop and sell lots of innovative drugs at low prices.

EQRx is seeking to mitigate technical risk somewhat by pursuing a “fast-follower” strategy in which the underlying target biology is relatively well-known, and it can learn and quickly adapt to development plans laid out by trailblazers in a new therapeutic category.

By reducing technical risk as a fast-follower, EQRx believes it can run faster, cheaper, lean and mean clinical trials with a higher probability of success. That would reduce its R&D spending and opportunity cost. If it can pull this off several times in a row, the diversified portfolio should give it the flexibility to price its ultimate products a lot cheaper. That’s the thinking.

Melanie Nallicheri, president and COO, EQRx

You might be skeptical. Plenty of people are. Drug pricing has been so dysfunctional for so long. So many vulnerable people in our society have felt exploited and gouged and ripped off for so long. They flat-out don’t trust the biopharmaceutical industry. The public has good reason to be skeptical.

There’s a lot here to think about, in terms of how pharma can and should operate, whether you agree or disagree with what Alexis and Melanie have in mind. It’s worth re-thinking especially in this new moment of crisis and collective spirit during the global pandemic.

I hope you enjoy this conversation.

Please join me and Alexis Borisy and Melanie Nallicheri on The Long Run.

23
Mar
2020

Let it Rip or Shelter at Home? Choosing Between Two Bad Options on Coronavirus

Otello Stampacchia, founder, Omega Funds (illustration by Praveen Tipirneni)

Like most of you, I have been obsessively following “the virus.”

It is having a devastating impact on human life, hospital systems, governments and economies. The worst is still to come, based on what we know about this new coronavirus and its ability to spread with exponential force.

Here are some thoughts on the difficult choices laying ahead.

Before I start, here’s a little on where I’m coming from. I have the dubious advantages of being at the same time Italian-born and a US-based venture capitalist active in healthcare. This gives me a lens into the government, healthcare and culture of a country that has been decimated, and an insider’s view into the scientific community and its prospects for counterattack (mainly therapeutics in my case). As an investor in public and private markets, math is part of the job, and I have a somehow intuitive feeling about exponential growth rates. Please refer to two previous articles on Timmerman Report, warning of the upcoming disaster on Mar. 10, and then on Mar. 18.  

As with most (all?) of you, I am watching the daily avalanche of terrible news and the public / policy responses trying to catch up to the inexorable progression of the virus. Note the use of the words “catch up” here, they will come in handy later.

In the US, we went from 89 confirmed cases on March 1 to ~41,000 as I write on the afternoon of March 23 (source: www.worldometers.info/coronavirus). The US, so far, has lagged far behind other countries’ in testing capacity and administrations, so it is catching up there as well. A patchwork of local, state and federal measures are being implemented across the country to try to limit the spread of the disease and preserve hospital capacity (and healthcare workers’ safety).

The economic fallout (at least the initial one) is also becoming starkly evident. Starting in late February, US stock market indices have to date lost ~$12 Trillion (herein shortened to “T”) in market value, or roughly 25-30% from their pre-crisis peak (I will strive to be roughly accurate versus precisely wrong throughout this article).

More importantly, entire sectors of the economy (employing a huge portion of the US workforce) are veering rapidly towards bankruptcy: the lethal combination of lack of demand and restrictions on movement has made their business no longer viable (in these circumstances). Hotels, restaurants, airlines, gyms, physical therapists, etc etc are making millions of people redundant across the board.

The US lacks (for the time being) social safety nets that are much more prevalent in other countries. That increases the severity and amplitude of these kind of shocks. The US economy generates about~$40T per year in gross domestic product. Of that, ~70% is composed of services and consumers’ consumption. It is painfully obvious to see how broadening, enforcing and / or continuing “shelter at home” policies in the US for a much longer period will cause incalculable economic damage. The chief of the St Louis Fed was quoted recently saying unemployment in the US could reach 30% in Q2 2020, and GDP could go down by ~50%. This is equivalent to what happened to the US economy during the Great Depression of late 1929 and through the 1930s, and it is happening at a much faster pace – a matter of weeks.

In this context, I see / hear / read a number of voices arguing for a “let it rip” strategy: i.e., continue “life as normal,” spreading the contagion without any radical social distancing measures, accepting that there will be a (slight?) increase in the number of casualties but preserving the broad health of the economy. This virus has a mortality rate of close to, and quite possibly, lower than 1%. On Mar. 16, disease modelers at Imperial College London, factoring in the best available estimates at the time, estimated that the novel coronavirus would kill about 2.2 million people in the US alone under what you could call a “let it rip” strategy – one that doesn’t utilize the disruptive social distancing interventions currently being imposed. A day later, Mar. 17, Stanford University epidemiologist John Ioannidis argued that “we are making decisions without reliable data.”

One of the basic arguments underlying the “let it rip” strategy appears to be the Precautionary Principle: “The precautionary principle (or precautionary approach) is a strategy for approaching issues of potential harm when extensive scientific knowledge on the matter is lacking. It emphasizes caution, pausing and review before leaping into new innovations that may prove disastrous.” (Wikipedia).

Spoiler alert: this discussion is based on fundamental flawed assumptions, at many levels. The (strongly worded, high conviction, HIGHLY evidence-supported) response to this “argument” should be: “(expletive removed) no!” If you carefully, cautiously wait for all the data to come in, your actions will come way too late. Also, interestingly enough, I will end up using the same Principle to argue exactly the opposite of the proponents of “let it rip.”

Now please bear with me as I try to discuss in some tedious detail why this is the case.

The Importance of R0 and Some Exponential Growth Rate Basics:

R0 (or R “naught”) is a measure of how many people one person infects. R0 = 0 (if you are by yourself on a desert island) means you will not infect anybody during the course of your infection; R0 = 1, means you will only infect one person. R0 = 3 means (ah, ok, I see that you got it by now).

For the sake of comparison, “normal” seasonal flu is considered to have an R0 of ~1.3-1.4. Coronavirus is considered to have an R0 of ~2.5-3.0. You REALLY want R0 to go below 1 to contain a pandemic. Importantly, in addition to depending on the virus’ infectivity, incubation period etc etc, R0 is ALSO LARGELY DEPENDENT ON PHYSICAL PROXIMITY. Simply put, if you have a highly contagious (possibly asymptomatic) Italian carrier in an Italian bar in Milan, every bar customer (and almost every surface) will be covered with virus by the time it takes to finish an aperitivo (kind of kidding, but kind of not kidding).

Now, let’s assume the coronavirus average infection cycle is ~4 days (meaning one person infects an R0 nr of people every 4 days). This is where problems start with exponential growth rates. What happens with 10 cycles following the initial infection(s) caused by that person: 10 incremental infection cycles (~1.5 months): normal seasonal flu (R0: 1.4): ~29 people infected. Coronavirus (R0: 3.0): ~59,000 people infected. That means one asymptomatic person, in this coronavirus season, leads to the infection of another FIFTY NINE THOUSAND (I thought that deserved all caps).

Professor Hugh Montgomery, Director of the University College London Center Institute for Human Health and Performance explains this really well (and with a better British accent that I could ever muster) in an interview with Channel 4 here.

The Problem is Hospital Capacity:

Again, please read the previous articles published on this topic on Timmerman Report from Mar. 10 and Mar. 18.

Basically, the important argument behind the “let it rip” approach is that a 1% fatality rate is a price (steep, but worth paying I guess?) for maintaining a functioning economy and not lose ~$1T / month in US GDP. We also do not know enough about the virus mortality rate, natural immunity etc etc so we should not “rush to judgment.”

I am not going to dignify the “natural / herd immunity” argument (there is no natural / herd immunity against the virus: it is a NEW VIRUS that no human on this planet has been exposed to before). What we know today about it is dwarfed by what we still need to learn.

First fallacy: consumption / economic activity will continue as “normal” should we lift restrictions on movements. I am really not sure how to address that one, unless it relies on the assumption that people are completely ignorant of the fact that there is a pandemic going on, and they’ll instantly snap back to life as normal once social distancing restrictions are lifted. Are you really going to take that trip to Milan for Easter now? Scheduling your wedding with all grandparents attending (knowing 1 in 4 of them will likely die if they get infected)? Assuming you could even board a plane, that is. (Full disclosure: my wife and I HAD a wonderful holiday trip planned to Milan to see my family there for Easter. Obviously, we cancelled).

Second, MASSIVE fallacy: the assumptions behind the 1% mortality rate. This might possibly end up being the “undisturbed” mortality rate, when it is all said and done: meaning, this SHOULD be the mortality rate IF you can obtain proper medical care (hospital bed, sufficient supply of oxygen / drugs if needed, caring and competent nurses and doctors).

Now is probably a good time to make the obvious argument that lean, efficient hospital systems (we are in a capitalist society after all) are not structured to be resilient and provide, additional capacity in a pinch.It is actually extremely expensive for a hospital to have spare capacity in terms of critical care beds, ventilators, nurses, doctors, drugs etc. So, they do not do it. Even countries perceived to be more like “social democracies” than the US do not have nearly enough spare capacity to tackle such a surge in cases. Italy has a very good hospital system. China, notwithstanding popular perception, has an excellent healthcare system, no lack of critical care equipment, and they moved 40,000 doctors into Wuhan’s hospitals to make sure they could cope. They also shut down the city when they had 500 officially diagnosed cases. Still, Italy and Wuhan had mortality rates skyrocket as soon as hospitals were saturated. Any incremental patient who needs oxygen (and cannot be properly tended to) will die. Mortality also greatly increases as hospital infrastructure degrades: you cannot fast track the training and education of new doctors and nurses in a few days. Healthcare workers are toiling under wartime conditions, getting infected themselves and dying. Which further compounds the lack of hospital capacity.

In addition, if hospitals get saturated / overwhelmed: every heart attack can become fatal if ambulances cannot reach you / hospitals cannot administer proper care. The US has ~1.5M heart attacks a year, causing ~500,000 deaths when proper care can be administered. The US has roughly 1.9M new cancer cases per year (source: https://www.cdc.gov/cancer/dcpc/research/articles/cancer_2020.htm). These patients are usually immunocompromised after getting chemotherapy or radiation treatment, which makes them very much at risk from opportunistic infections like this coronavirus. In addition they need urgent, critical treatment to achieve remission. In 2018, 34.2 million Americans (10.5% of the population), had diabetes (source: www.diabetes.org/resources/statistics/statistics-about-diabetes). Apparently, diabetics coronavirus patients have a much higher mortality rate. We don’t really understand why that is yet. The list goes on.

One (scary, but I believe accurate) way to look at this in the US is to check out the website www.covidactnow.org: it simulates by when different US states’ hospitals will be overwhelmed by the number of confirmed  cases of infection, depending on how we slow down the virus by using different types of social distancing measures to reduce R0 as much as possible.

As you can see, for a number of places, in particular NY, it is too late already. The number of cases will continue to mount over the next two – three weeks. This is why New York Gov. Andrew Cuomo (I cannot help but appreciate another fellow Italian’s decisive response) has asked for federal assistance, and is trying his best to increase hospital capacity in the city. May the fates be always in his favor as well.

Finally, please read Tomas Pueyo’s insightful blog post on this as well. Conclusions are similar to what you will find herein and in my Timmerman Report from Mar. 10.

Bottom line: “let it rip” is not sustainable. The economic and (more importantly) social cost of the disease is going to be even higher than if we undergo a 3-4 weeks shut down. Assuming even modest degradation of the US healthcare infrastructure, the death toll could rise to much more than 1% of US population (about 329 million people currently, according to the US Census Bureau).

But: We Cannot Have Radical Social Distancing for 18 Months!

True, it is not sustainable to have the global economy on lockdown for 18 months. Most important, people cannot comply with such isolation measures (especially those pesky, frolicking fools celebrating Spring Break in Palm Beach). Absolutely agree on that.

OK, here then are some thoughts (feel free to pass them along your favorite policymakers): in temporal sequence from now:  

1. We (the US) need NOW a nationwide, ideally even globally-coordinated, “pause” of 3-4 weeks at a minimum, with as little movement of people as possible, across the entire US. I mean a shut down like Italy, enforced by police etc to make sure these frolicking teen fools in Palm Beach (see above) do not continue spreading the virus; no travel unless absolutely necessary. Note: from the moment you impose and enforce such a lock down, then it takes ~2 weeks for cases and deaths to reach a peak. They will continue going up in the meantime. New York City now is like Milan and could become very soon like Bergamo otherwise. ALSO NOTE: two weeks after you impose such a lockdown, things improve. Italy has now turned the corner: in the last two days, the number of new confirmed cases and most importantly, number of fatalities, is decreasing. The lockdown in Italy started on Mar. 9, exactly two weeks ago.  

2. There needs to be absolutely clear and effective communication from the federal government. They need to enlist any traditional media sources and social media (Twitter, Facebook) with a simple, clearly communicated message: Social distancing / stay at home will work to reduce the infection rate; BUT it needs 2-3 weeks to show some results and it NEEDS TO BE ENFORCED. Our social structure and citizen relationship to authority is very different from Asian countries: but this means even more clear communication is absolutely necessary. We need to enroll every citizen in the effort. Make sure supply chains / logistics distribution / food and essential medical equipment manufacturing / energy production / broadband infrastructure can take the strain. All these activities can enroll people otherwise made redundant by the industries most affected.

3. In the meantime, during that pause period:

  • Increase massively testing capacity and manufacturing (I mean, massively: the only way to resume some semblance of normal economic activity after the lock down, and only IF we have put R0 below 1 by then, is by having RAPID tests available on a massive scale). Including providing serological tests to make sure immune people can roam around freely (and ideally be enlisted in the healthcare / manufacturing effort).So, drive-thru tests, at home easy-to-use tests, phone booth tests, all within a few minutes ideally; and not administered in hospitals where infections can otherwise cluster.
  • Increase hospital capacity and resilience: identify and staff separate physical hospital structures and caregivers for cancer patients; increase ICU and critical care capacity (ventilator manufacturing, etc ). Every city with an international airport needs to be prepared for surges in cases; train more nurses, doctors, to prepare for the onslaught; use / adapt hotel structures in big cities for isolating people tested positive (including asymptomatics); divert car manufacturing to more ambulances; increase manufacturing for oxygen, painkillers for intubated patients, etc.
  • Have separate structures (hotels? island resorts?) for at-risk demographics: elderly, people with co-morbidities (diabetes).They need to be completely isolated for ~10-12 weeks, at least until prophylactic treatments are available (Japan has been using this strategy very successfully).This will reduce death rates and preserve hospital capacity; these structures can be staffed by (for example) airline staff who has recovered from the virus already.
  • Massive increase in R&D spending: vaccine / antibody manufacturing capacity. We must start GMP manufacturing of all drugs that potentially look likely to work in pre-clinical models so we do not lose time for scaling up manufacturing. Diagnostics need R&D support, as well (Korea and China have portable CT scans, for example). There’s no time to lose. Every month of a lockdown the US loses >$1 trillion of GDP.

4. The other stuff (how to make sure workers maintain healthcare insurance), can still survive if tens of millions of people are unemployed starting next week etc. This is way above my pay grade but also super important to make sure we can come out the other side.   

We will come out of this. But, the next 6-8 weeks are critical in preserving our hospital infrastructure. The virus spreads way faster than you think. If we delay implementing these measures even a couple days more, the consequences are disastrous. The math is inescapable.

To leave you on a lighter note, and a perhaps more entertaining take on how efficient technocracies should make decisions (versus the dilemmas facing politicians), this video clip from the old British show “Yes, Minister” is priceless. Moral: I hope we can stop listening to other “opinions” and start listening to the science.

Follow Otello Stampacchia on Twitter: @OtelloVC

This article expresses the personal views and perspectives of the author. The views and perspectives expressed here do not necessarily represent the views or perspectives of Omega Fund Management, LLC or any officer, director, partner, member, manager or employee of Omega Fund Management, LLC or any of its affiliated entities.

22
Mar
2020

Why Telehealth Champions Are Worried About Trust

David Shaywitz

Crises can serve as catalysts. History has shown they increase the recognition that change is needed, and lower the activation energy required for it to occur.

The COVID-19 crisis has already been widely recognized as potential catalyst for telemedicine, and more generally for the accelerated adoption of digital tools in both clinical medicine and clinical trials. In just the last week, the FDA released urgent new guidance (here, here) seeking to smooth the way for both.

The surprise is: some of the most ardent champions of digital health are thinking critically about the current moment, warning that if we abandon vitally important safeguards in our rush to embrace technologies, the adverse impact on patient trust will poison the field for decades to come. Moreover, they argue, even in a crisis, you don’t need to choose between rapid execution and good data privacy rights – indeed, they suggest, especially in a crisis, we can, should, and must push for both.

***

Telemedicine has long seemed like an application of technology particularly well suited to pragmatic incorporation into care, enabling patients and providers to engage remotely, without the time and aggravation of traveling to a medical office.   

In concept, it embodies at least some aspects of the house call, albeit without the laying on of the hands.

Yet, telemedicine long struggled for real traction. Some, like Eric Topol, a thought leader in this area, believe that “[the] past decade saw telemedicine finally cross [the] chasm,” described by Geoffrey Moore, where the adoption of emerging technology moves from a few visionaries to the “early majority of pragmatists,” as Topol and E. Ray Dorsey recently wrote in The Lancet

Others would surely argue that even if telemedicine hasn’t quite crossed the chasm in most areas, it is at least getting close. But almost everyone agrees that the adoption over the past two decades has been much slower than many had expected.

Why has telemedicine been such a hard sell, especially in an age where consumers routinely use their phones for everything else?

To oversimplify only a bit, a big part of the answer is: incentives. Providers have struggled to get paid for telemedicine, at least at levels comparable with in-person visits. As venture capitalist and health systems expert Bob Kocher says, Medicare requires an in-person visit before a patient can access care virtually, and even then, the reimbursement for a telemedicine visit tends to be relatively low. 

My Tech Tonics co-host and digital health guru and investor Lisa Suennen agrees reimbursement is an important issue –“telehealth-provided services needed to be reimbursed the same as the equivalent service provided in person,” she says. As Peter Antall, chief medical officer of telehealth company American Well recently told STAT’s Erin Brodwin, “The reimbursement challenge still exists for telehealth,” a lament echoing the complaints of genetic testing companies a few years back.

Suennen also highlights another challenge: the need for in-state medical licensure adds another wrinkle: a licensed California physician can’t provide telecare in New York — or Nevada, or any other state — unless she is also licensed in each of those states. The burden is therefore on the practitioner – who’s already loaded with responsibilities — to jump through a series of hoops to get licensed in multiple states if they want to create a thriving telemedicine practice. By design, this makes it more difficult for less busy physicians in one state to ease the burden of overwhelmed doctors somewhere else.

An additional hurdle, physician-entrepreneur and telemedicine guru Dr. Seth Feuerstein points out, is “general inertia in a system filled with risk averse folks who have little or no incentive to do things in a better way.”

Add to this the problem of what Kocher calls “clunky technology.” As Suennen points out “some technologies are really good and some aren’t – you need to choose wisely.”  (Providers generally need to use technology that is compliant with HIPAA regulations, meaning you can’t just use whatever consumer videochat app you have available.)

Yet another often appreciated challenge is cultural: as one expert pointed out, “some doctors don’t like the loss of control” that might be associated with telemedicine. Suennen says there’s a lot of “provider discomfort” with the idea, and many don’t like being on screen.   

Many patients are equally reluctant to change; Kocher cites as another barrier “the lack of demand by patients who are happy with the status quo.” Or as Suennen bluntly puts it, “people still want healthcare mostly from people” rather than videoscreens.

* * *

Enter the COVID-19 crisis, which has changed, at least for the moment a few key factors.  Today, both patients and physicians are highly motivated to minimize clinical visits, which intrinsically introduce an increased risk of infection for both physicians and patients – hospitals and clinics are good places to avoid these days, if at all possible. 

In addition, some reimbursement and HIPAA barriers have been waived to make it easier for seniors to access telecare, and for physicians to get reimbursed for this – changes that actually unleashed a tidal wave of demand that overwhelmed telehealth providers, according a recent STAT article. (STAT’s coverage of the pandemic in general, and this aspect in particular, has been superb.) 

Of course, many of these COVID-19-motivated changes may revert after the pandemic subsides.

On the face of it, the crisis would seem like a transformative opportunity for telehealth (at least once the initial crush of interest is managed). Yet, as I spoke with a number of savvy stakeholders who have been champions of digital health, I was struck by their caution, which seems almost more prominent than their enthusiasm. 

The key issue for many, including Andy Coravos, CEO of Elektra Labs, and Eric Perakslis, a Rubenstein fellow at Duke, is precisely the potential of a crisis to drive – and justify – significant change. Both Coravos and Perakslis advocate for the importance of privacy (Coravos prefers the term data governance). They both emphasize that even in a crisis, we must not be lulled into a perceived false choice between speed and privacy (or speed and good governance).

Coravos and Perakslis contend that there are plenty of opportunities to have speed and privacy, and argue we should push citizens and governments to renegotiate for those opportunities. Privacy policies, terms of services, and end-user-license agreements can be re-written during public health emergencies, they suggest, to protect those who are vulnerable. Hospital systems, governments and others purchasing on behalf of those who cannot make these decisions, Coravos and Perakslis emphasize, can and should factor these considerations into their procurement negotiations. (For more on the risks of data governance in telehealth, see this recent opinion piece in STAT by Kirsten Ostherr). 

The core issue, Coravos suggests, is trust; for telemedicine and other digital tools to truly gain traction, users need to be able to engage these tools with trust – trust in the fidelity of the measurement, and trust that the data won’t wind up being used, without their permission, to sell them ads (best case), or deny them insurance, a worrisome concern.

For Coravos, the key opportunity of a crisis isn’t to accept the necessity of a false, bad choice — such as supporting public health at the cost of personal privacy — but rather, to use this moment to push for strong governance, so that the tools and approaches developed at this moment of need will earn the trust needed to support their use once the emergency has passed.

A particular concern raised by Perakslis is that, in the context of the crisis, many “people are running in with dubious products and solutions,” adding “lots of dodgy stuff is going on.” Echoing the flavor of concern raised by Coravos, Perakslis adds he’s very worried that “Silicon Valley and the VC world are pushing for relaxation of every basis of regulation and ethics.  The harms will be significant, and this could set things back.” In other words, if people don’t trust the system, they won’t willingly participate in the system, especially after the pandemic is over, and perhaps even during the current crisis.

Adds Coravos: “Good regulation is a necessary precondition for innovation because it creates trust in a system.”

Bottom line: The COVID-19 crisis has created a potential breakthrough moment for telemedicine and other digital technologies.  But if these aren’t implemented with care, security and good data rights, any short-term benefit is likely to be offset by the corrosion of trust critically required for enthusiastic patient engagement and long-term success.

20
Mar
2020

In Times of Coronavirus Pandemic, it Takes a Global Village

Praveen Tipirneni, CEO, Morphic Therapeutic

For some US biotech companies today, the ability to maintain business and societal continuity during the COVID–19 pandemic comes with assistance from a surprising source.

Contract research organizations (CROs) based in China were the first – and most severely — impacted by the new coronavirus outbreak in January. But they are now rebounding to provide their traditional services to biopharma clients worldwide, and they’re doing it with an extraordinary level of dedication during COVID-19 disruption.

It has been reported that China is mounting a “diplomatic offensive” through generous donations to Europe. On Wednesday, Mar. 18, China said it would provide 2 million surgical masks, 200,000 advanced masks and 50,000 COVID–19 testing kits to Europe.

“We’re grateful for China’s support,” Ursula von der Leyen, the president of the European Commission, said in a tweet. “We need each other’s support in times of need.”

Social media is ablaze that China is seeking to build stronger relationships with America’s traditional allies, and that this is what happens when American diplomacy looks inward. That may be so on a macroeconomic and geopolitical scale. But on a microeconomic and social scale, it’s quite a different story, at least for some US biotech companies working in collaboration with Chinese CROs.

A significant percentage of all US biopharma companies rely on contract research conducted in China. There’s a reason: many of these companies perform first-rate work, meet their deadlines, and do it all at a lower cost than in the US or Europe.

So, when the SARS-CoV-2 virus began spreading in Wuhan and its surrounding Hubei Province, and the ensuing COVID–19 respiratory illness prompted a lockdown in China, it was immediately a cause of concern for the majority of US biotech companies who depend on work being done to develop their drugs in China.

The drastic containment measures and work disruptions in China rippled through US biotech almost immediately, throwing wrenches into product development timelines.

Two months later, the story is quite different. The US is now rapidly beginning to implement severe containment and mitigation measures. The FDA, the regulatory agency that all companies must work through to keep new drug applications moving along with proper designs, is operating at reduced capacity. Social isolation is the new norm.

Meanwhile, many CROs in China are returning to, or are already at, full capacity. Their current efforts extend far beyond making up lost productivity though – more on that to follow – but include acts of kindness and assistance that symbolize a gesture of global solidarity during an unprecedented interruption in society and business.

Morphic Therapeutic is a Waltham, MA-based company developing small molecule inhibitors of integrin receptors (See previous Timmerman Report coverage of our company in June 2016 and October 2018).

We work with several CROs in China. Cheng Zhong, a chemist at Morphic, has experienced unexpected support from a CRO in China that he feels is an effort to work side-by-side with customers who have become friends during times of need.

For example, Zhong recently received an email from a counterpart in China offering surgical and N95 masks because the partner was unsure if masks were freely available in the US. Dr. Zhong accepted the offer and immediately received the shipment of masks via express delivery.

The following is an excerpt from the email sent by his counterpart expressing their hopes for a return to normalcy in business – and the personal wish that the leader of Cheng’s team, Blaise Lippa, would be able to have the simple experiences that are so often taken for granted:

“Just as Cheng said, we fight together and we win together!!! I hope Blaise and his son could watch the NBA games together very soon.”

The stories move further than goodwill and friendly support. In late February, Morphic inquired about the potential impact on our research timelines and when operations might return to normal.

The reply from the Chinese CRO was surprising and heartening:

“In order to make up for the lost week of work, we plan to create a work schedule for everyone that can come and make up during weekends. Starting this weekend, each chemist will first make up 5 days, by working on the following Saturdays until early April.”

Others in the biotech community have experienced similar collaborative efforts by companies in China to deliver on shared projects despite the challenges with the new coronavirus restrictions.

Mark Tebbe, co-founder and chief technology officer, Quench Bio

Mark Tebbe is co-founder and chief technology officer of Cambridge, MA-based Quench Bio, another company that relies on contract research work in China to support operations. Quench discovered behavior that embodies alignment beyond the traditional vendor-client relationship.

“We worked through plans with them as they were returning to work – ensuring they stay safe but also get paid. They were acting as true collaborators not as fee for service vendors,” Tebbe said.

Shakti Narayan, CEO of Lexington, MA-based Accent Therapeutics, shared a similar experience that may provide assurance to US companies as they face escalating impact from the pandemic in the US – and as they increasingly rely on their Chinese counterparts to keep research moving.

“As virus went West, the Chinese CROs came back online much quicker than anticipated. And it was not just a gradual return, they came back to 100%. I was very impressed with the level of productivity and speed which they were able to come back online,” Narayan said.

Shakti Narayan, CEO, Accent Therapeutics

As the CEO of Morphic however, like leaders of many companies, I remain cautious and concerned about the global impact of COVID-19. But our company is also energized by the solidarity we feel with collaborators around the world. It’s inspiring to see their efforts, which exceed the already-impressive standards they operate under in normal times.

In a turn of events that illustrates how rapidly the conditions are escalating, scientists at Morphic became aware of more acute shortages of personal protective equipment at Boston-area hospitals after they received the masks from our China-based CRO. The Morphic scientists, in turn, arranged to donate most of the PPE to healthcare workers on the front lines of COVID19 diagnosis and treatment in our community, the Greater Boston area.

In these tumultuous times of pandemic, these collaborative efforts may be summarized with a final excerpt from the email to Dr. Zhong:

“Seneca said: We are waves of the same sea, leaves of the same tree, flowers of the same garden!”

19
Mar
2020

Singapore: What We Can Learn From a High-Risk Country’s Response to COVID19

Carolyn Ng, managing director, Vertex Ventures HC

I was born in Malaysia, but left my family for the promised land of Singapore at the age of 12 under a scholarship program known as the ASEAN program. I lived more than half my life in that country, and have long since become a Singaporean. I currently manage a major Singaporean life sciences VC fund from a San Francisco Bay Area office.

Since the first confirmed case was identified in Singapore 55 days ago, the country has done a remarkable job of containment and mitigation. As of this writing, there have only been 313 confirmed COVID19 cases in Singapore with no COVID-related deaths. Those are remarkably low numbers compared with South Korea, Italy, Iran and other countries.

While Singapore is bracing itself for a spike of cases (more on that later on), what has worked well thus far?

The Beginning

Having lived away from home since I was a child, I make it a point to return to Malaysia and Singapore every year for the Chinese New Year festivities in late January / early February. It makes my parents and family happy. It brings me joy, too.

This year was no different. My fiancé and I flew back to Singapore, and took a rental car across the border to Malaysia. We landed January 23. That was the day Wuhan city was locked down to curb the spread of what was then just called the “novel coronavirus.” That same day, Singapore reported its first confirmed case of the illness we now call COVID—19. The coronavirus was all over the news in the ensuing days. Fear and confusion about the virus loomed over our lunar new year festivities.

Three days later, when my family crossed the border from Johor Bahru, Malaysia to Singapore, things had changed. On January 26, after the first FOUR confirmed cases of COVID19, we were told that every single traveler entering Singapore by plane, by foot or by car will have his or her temperature taken.

Something You Should Know About us Singaporeans

Before I go any further, there is an interesting Singaporean concept I need to introduce to our readers: it is called “Kiasi.”

“Kiasi,” in Hokkien (a common dialect in multi-lingual Singapore), literally means “afraid of death.” Those familiar with the history of the country would understand why. Singapore was kicked out of Malaysia in the 1960s in the post-colonial times, and was left to fend for itself with no clean water supply and zero natural resources. It is no wonder that this mentality of “the need to survive,” or the “fear of death,” has been core to the survival and later on, the flourishing of this nation city.

And this national mentality has, despite its derogatory connotation with cowardice, served us particularly well in times of crisis. I remember vividly living through the dark days of SARS in 2003. We lost 33 precious lives out of the 238 confirmed cases. Many in the US and elsewhere might scoff: “33? Did you say 33? Does this small number matter?”

Yes, to a small nation with a “Kiasi” mentality, IT MATTERS. Ever since SARS, Singapore has become much more crisis-ready.  

Learning from our SARS experience: There Is No Time to Lose

The SARS experience, and, more importantly, the willingness to learn from the experience, is now paying off. The country is bracing itself now for the worst of COVID19 spread. Singapore is particularly vulnerable, given that it is one of the most densely populated city states in the world. with 5.6 million inhabitants in 278.6 square miles — about 25% more densely populated than San Francisco. It’s also one of the top destinations visited by tourists from Wuhan, the epicenter of the outbreak. Given what we know about where the infection started, and how it spreads in densely populated spaces, Singapore is in a particularly vulnerable position.

In recent days, I had the opportunity to chat with a long-time friend, Dr. Jeremy Lim, co-director of Global Health at the Saw Swee Hock School of Public Health at National University of Singapore (NUS). He and his colleagues are doing incredible work treating migrant workers pro bono at a non-profit clinic. Dr. Lim has been at the frontline of Singapore public health policies for most of his career.

He shared that Singapore’s multi-ministry COVID19 task force was formed BEFORE the country even had the first confirmed case. This decisiveness and strong political will in taking forceful actions have been key. Public health and top political leaders have been aligned since the start on a fast, systemwide effort to prevent a pandemic.

It is also noteworthy that the country, despite its dense population, has been able to control the COVID19 situation without a city/countrywide lockdown. While it remains to be seen if the city state can hold out much longer before taking that type of draconian action, it does warrant some attention to review what have worked well to date.

It is not that interesting nor helpful to list out every single measure in boring technical detail, so I would like to discuss them thematically instead:

1. Concerted Political Effort and High Level of Transparency

Instead of wasting precious time politicizing the issue, ignoring the issue, or pointing fingers at our neighbors who might or might not have started or worsened the COVID19 crisis, the Singaporean government focused since the early days on mounting a concerted effort with strong political will in ensuring its success.

For example, a 14-day quarantine in Singapore for those who have been suspected to have been exposed to the virus, is not a “we are advising you to stay at home and we think you most likely will” type of exercise. There are at least THREE daily spot checks done by video conferences at random hours every single day to ensure that households under quarantine are indeed staying at home. Punitive measures are taken against those who violate these quarantine rules. The government is not fooling around with this and the administration executes its plans with exceptional efficiency.

2. Transparency, Data availability, and Clear Communication

The government has been extremely transparent in the number of cases confirmed, with full details of the background of the patient, along with the source of the infection. The authorities took painstaking effort in contact tracing. Every single case is laid out clearly on this official website.

The country’s leadership consistently and clearly communicates directly with its citizens, and control local media outlets to carry public messaging of washing hands and social distancing. Singapore has always been under fire for the lack of freedom of speech, but in this crisis, it has helped to curtail the spread of misinformation in Singapore. It has also avoided the entire “this is serious” versus “this is just a flu” kind of public debate. The message is unmistakable to everyone — common folks must do what is socially right to curb the spread of the virus.

3. Strong Fiscal Support for Those Affected

The government was quick to decide that all patients, whether confirmed to be positive or negative, will not have to bear the cost of COVID19 testing. Hospital bills for all confirmed and suspected cases are to be footed by the Ministry of Health. Self-employed individuals who have to be quarantined at home even receive $100 per day from the government. Lastly, it was made a rule that employers are not allowed to deduct paid-time off from employees for their days spent in quarantine.

In times like this, these measures matter tremendously to the affected pool of population and also help contribute to compliance with the quarantine measures.

Even for those households who have not been infected, the government has distributed four face masks to every household. Hand sanitizers were also distributed to support those in need.

4. Strong Collaboration Between the Government and the Scientific Community

China shared the sequences of SARS-nCoV-2 – the virus that causes COVID-19 — with the international scientific community on Jan. 11. Immediately, scientists at all the institutions of Singapore, private and public, were urged to work collaboratively on developing diagnostic tests, which were in dire need. By late January, Singapore-based Veredus Lab announced the development of its VereCoV detection kit. On March 3, Singapore’s Health Science Authority approved the provisional use of the test kit as an in-vitro diagnostic product. This effort was not done solely by the biotech company though, but as a collaborative effort between Veredus and a statutory board under Singapore’s Ministry of Home Affairs.

A research team in DUKE-NUS Medical School developed serological testing that was used for establishing links between COVID19 clusters. This test, based on virus-specific antibodies, has been used by Singapore for effective contact tracing.

There Have Been Mistakes

Not every system is perfect, and neither is Singapore’s. On Feb. 7 (with still only four confirmed cases), officials announced a national alert at the “Orange” level. Orange was the same level of alert triggered by the SARS pandemic, which so many citizens vividly remember.

The Feb. 7 announcement induced a panic, as citizens cleaned out the shelves of grocery markets overnight. This was neither the most gracious nor rational reaction. Singapore’s Prime Minister Lee Hsien Loong had to go on television to urge calm and to tell people that there is “no need to stock up with items such as instant noodles or toilet paper.”

As Jeremy Lim remarked, in hindsight, the upgrade to DORSCON Orange could probably have been better communicated to avoid public panic. 

Moreover, it is unknown whether Singapore is able to scale its healthcare infrastructure and workforce to cater for a “real” spike in COVID19 cases. Unfortunately, unlike China and other countries, Singapore has no hinterland or other provinces/states to draw resources from.

The Crisis Is Not “Over,” Not Even for Singapore

The Singapore government has just mentally prepared its people that numbers could remain high in the coming days, as more Singaporean students and workers return home because of lock downs in cities around the world.

In addition, in a dramatic turn of events, my birth country Malaysia just ordered a countrywide lock down on Mar. 18. This ruling has a severe impact on the 300,000 people living in Malaysia who commute across the border every day to work in Singapore. As a result, there was an insane rush of at least 100,000 people trying to cross the border into Singapore before midnight on Mar. 18. The Singaporean government is now working round the clock to find housing solutions for these 100,000 Malaysians who made it through the borders, with subsidies of $50 a day provided to them.

With this episode of mass border-crossing, it is only to be expected the country will experience a spike in COVID19 cases in days to come. Singapore has not had to impose national lock down so far, and although its containment measures have been reasonably successful, time will tell if this still holds.

I pray for my ENT doctor brother working at the front line in a hospital in East Malaysia, for those being affected back home in Singapore, and to my new beloved home the United States. We have lost precious time. We have to put all our political and ideological differences aside to get over this crisis together with swift and decisive actions.

Disclaimer:

This article expresses the personal views and perspectives of the author. The views and perspectives expressed here do not necessarily represent the views or perspectives of Vertex Ventures HC, or any officer, director, partner, member, manager or employee of Vertex Ventures HC, or any of its affiliated entities.

18
Mar
2020

8 Days Later: Italy vs. US

Otello Stampacchia, founder, Omega Funds (illustration by Praveen Tipirneni)

The following is an update to my article on March 10, also published on Timmerman Report. The initial article is available (free to read here).

Before I begin, I would like to sincerely thank everybody who has reached out with comments / feedback after my first article. Thank you also for the outpouring of well wishes for my family in Italy. So far, they are all safe and sound (though increasingly going stir crazy from being locked up in their homes: you should really see the videos going around our family’s social media. They are hilarious).

So: it’s been a bit more than a week since that note of warning. Where are we now?

Unfortunately, the daily situation in Italy has continued to worsen: as I write, Italy has had more than 31,000 confirmed cases and over 2,500 fatalities. This is a Case Fatality Rate (CFR) of ~8%. If any more proof was needed, this is not the flu. China, where the outbreak began, has had a total of ~81,000 cases and ~3,100 deaths. Italy is quite likely to surpass China’s fatalities shortly (it has almost as many fatalities after 21 days as China did after 35). Note Italy has a population of ~60 million, compared with a Chinese population of ~1.5 billion.

Of course, China led the crisis response by initiating drastic social distancing measures and testing, followed by quarantines among those infected, very early on. These draconian actions probably did save a lot of lives.

As shown in the chart below (from the FT), other European countries (UK, France, Spain) are more or less tracking a similar path to Italy. The Spanish situation is even more dire than Italy at a comparable stage. It is to be hoped than the severe quarantine measures which have been put in place will contribute to “bending the curve” back to reduce the death toll. There is no time to lose if we want to preserve hospital and healthcare system infrastructure to adequately care for the 15-20 percent of those infected who require hospitalization.

Also from the chart above, the US seemed (at least at the beginning) to be following a very different curve from European countries, at least so far: it appears almost as benign as South Korea (which has had an exemplary response to the virus and has managed so far to contain the outbreak and limit the number of fatalities). As I write, the US has had ~6,500 confirmed cases, with ~116 fatalities, for a CFR of ~1.8%. Considering the US has had very limited testing capacity online to date, this is remarkable. Note, however, the curve seems to be steepening, not bending down.

I can almost hear your thoughts: this is not THAT bad! We are winning this! We are almost as good as South Korea! (I knew I did not have to study math in high school…). Why are we worrying about this virus so much AND shutting down the entire economy?? I do not want to be stuck at home with my children all day!

I will argue below that this is not necessarily the case. We are NOT “winning.” Again, I do hope I am wrong. Please bear with me as this becomes a bit wonky below (and yes, you should have studied math in high school).

We Are All Living in the Future

This is an important point.

I think I know most of the people who read this newsletter: you are living in the now, avidly watching today’s news. And I assume, as readers of the Timmerman Report, that you are well informed and are up to date with the zeitgeist. Good for you. Sorry to disappoint your own self-esteem, but that is not necessarily accurate for this situation.

To clarify: it takes ~17 days from initial infection to death on average. Fatalities we see TODAY are people who were infected more than two weeks ago.

Today’s news (and the increasing level of panic in financial markets, our own social networks, etc.) is based on the equivalent of the information coming from the light from a star (17 light-days away, ~3.6*1011 km, roughly 100x farther away than Pluto, you can make your own conversion in miles if it is important to you). It was sent out 17 days or so ago. That star might as well have exploded since and you will only find out in 17 days (and what a great sunburn that will be).

Therefore, to recap, the fatalities reported TODAY are a snapshot of infections that happened THEN, not NOW.

Since then, remember the virus spreads exponentially, with an R0 (a measure of infection spreading, no need to get into that now) that is very high without social distancing measures. The R0 can be moved in a lower, more manageable direction with aggressive social distancing. But the US did not put those type of strong interventions in place until recently. And as of this writing, they don’t extend to every geography in the country.

One consequence of us living in the future is that, even if you start immediate, radical social distancing measures right NOW, the number of infections and fatalities reported will continue to climb for those ~17 days. Italy’s fatalities have grown almost 10-fold since northern Italy begun its quarantine.

Testing is (VERY) Important: Asymptomatic Carriers Contribute Massively to Spread

Let me introduce you to the small town of Vo’, in Veneto, West of Venice (Italy, not California). The town was in one of the initial cluster of cases in Northern Italy, and is close to the University of Padova, where there happens to be a great virology department, led by Prof. Andrea Crisanti.

The town’s mayor, may the fates be always in his favor, decided to test EVERYBODY in the town (~3,300 people). He tested them TWICE, at a distance of 10 days. In the first round of tests, ~3% of the town (~88 people) was infected. Asymptomatic carriers were the majority of infections detected (50-75%, I cannot seem to nail that number down from my Italian sources). Everybody infected, including asymptomatic carriers, were isolated (including from their own families). In the second test, 10 days later, the number of people infected had gone down to 7 from 88 (these were new cases who somehow had gotten infected in the intervening period). Now the town is virus free.

An article recently published in Science (Li et al., Science March 16, 2020, DOI: 10.1126/science/abb3221), using Chinese data, also broadly corroborates this finding. According to that article, ~86% of infections are estimated to be undocumented prior to the Jan 23 travel restrictions put in place. Undocumented infections (which for all intents and purposes we can understand to be asymptomatic, though that is not a 100% accurate assumption) seem to have a transmission rate of as much as ~55% of documented infections. However, because of their much greater number, undocumented infections were the source of almost 80% of documented cases!

What this means is that huge numbers of people – for practical purposes, let’s assume almost everyone you could potentially come into contact with over the course of a day – could be spreading the disease without even displaying symptoms. 

This again validates the Chinese and South Korean approach of population-wide, massive rapid testing. Once cases are confirmed (and note that individuals are held in isolation away from hospitals and families, while tests are underway), the infected individuals are isolated (even if they aren’t displaying symptoms). Note that the information from Vo’, though on a small sample size, seems also to indicate that isolating infected individuals seems to prevent the disease from evolving into a severe state.

These experiences and data point to a very important lesson: there is a very direct trade-off between capability to perform lots of (rapid) tests and the need to impose radical social distancing to prevent healthcare system collapse. The more you frequently test AND isolate individuals infected (including asymptomatic spreaders), the lesser there is a need for radical social distancing.

Unfortunately, the U.S. did not heed this lesson from Korea (Japan did not perform extensive testing, but they did isolate their entire demographic of >70 year olds, thereby reducing the fatality rate so far). The lack of testing in the U.S. has contributed to possibly quite widespread community-based spreading.

The implications of this are very broad, particularly for the young demographic in the U.S. population (the U.S. skews young, see below): your partying and drinking in bars and restaurants during St. Patrick’s Day is not helping here. Stay home. One case, early in the outbreak, infects ~2.5 people on average (many, many more if in close physical contact like at bars, dance parties etc. I would not know personally, I am a terrible dancer, but so I am told). ONE SINGLE CASE, under those assumptions, can lead to ~244 more cases in one month. If you halve that transmission, by reducing social contact, that single case only infects 4 people in that month.

Now is a good time to teach young people about exponentials before letting them go out in the evening.

Viral Load is Also VERY Important for Disease Severity

The latest news from Italy is that ~9% of the fatalities are healthcare workers. This is tragic. These individuals have been working selflessly for weeks now in conditions akin to a World War II conflict zone, performing triage on patients, without adequate supply of protective equipment and often in isolation from their own families.

It also seems to point out that it matters how much of the virus you are exposed to when you are infected. These heroes on the frontlines are exposed to high virus titers for long periods of time.

It makes sense: the lesser the number of copies the virus has infected you with to begin with, the more it has to replicate (and the longer that takes) before it overwhelms your immune system. Logically, if fewer copies of virus enter the body in the first place, that gives the immune system more of a chance to adapt to the invader and mount a defense.

So: wash your hands. Stay home. ESPECIALLY stay away from people at risk (immune-compromised cancer patients, people with co-morbidities, etc.). The government needs to step up manufacturing of protective equipment for healthcare workers ASAP.

Social Structure & Demographics Makes a Difference

So back to the graph above. Yes, I hear you thinking: your graph (it is not “my” graph, but whatever) says we are doing better than the Italians so far. Almost as good as the Koreans! I thought we were winning (everybody likes winning, I get it) and you have not provided me with any counterfactual. Am done reading this!

My, what an impatient bunch. Go watch some less complicated news channels (lots of choices there) and then come back when you feel like you want to discuss complex issues. This is important.

Differences in social interactions and social networks seem to play a very important role early on in the epidemic, especially when coupled with different demographic structures (huge thanks to Prof. Moritz Kuhn at University of Bonn for publishing on this, I really invite you to read his stuff, he is on Twitter at @kuhnmo).  

Let’s start from the assumption that the virus was imported in Europe from mostly work-related travel. Different European countries are (very roughly) split in two categories: “A” countries, where grandparents do not live with their children and their grandchildren (France, Switzerland, Netherlands, Germany), and “B” countries (Italy, Spain) where there is a larger % of the population (close to 23% in Italy) in households with the three generations living together.

In “A” countries, the initial exposure of the elderly to the outbreak will be limited. This will lead to an increase in infections overall but with a reduced initial fatality rate (like we see now in Germany, and we saw earlier in France).

In “B” countries (sadly, Italy and Spain) the most at-risk demographics are exposed relatively early in the outbreak. This overwhelms hospitals sooner.

If I were to guess (remember, I am a recent guest to this country), the U.S. is an “A” country. So, I would assume that elderly demographics were less exposed early on at the population level.

In addition, the overall demographic skews much younger in the US. Have been trying to find graphs but I do have a day job. Trust me on this, Italy is overall a much older country (see all those monuments in Rome? Yes, current day Italians built those).

This factor probably helped reduce the initial fatality rate in the US. That is, until the epidemic has spread broadly enough that the cases reach more at-risk populations in the country.

This seems to explain the observation that infection growth rate (growth in nr of cases detected) in the US is actually higher than in Italy to date BUT fatalities are much lower to date (worryingly, starting to curve up).

When Hospitals are Overwhelmed, Fatalities Climb Rapidly

This is what worries me the most. See what is happening in Italy, Spain, look at the initial data from Indonesia, etc. etc.: all with CFRs exceeding 5-6%. As soon as hospital systems are overwhelmed, conditions resembling war zones start to apply and people who normally would have recovered in a healthy, functioning healthcare system are unfortunately not able to and perish.

We should not let that happen. Demographic and social structure have probably given us all a (short?) reprieve. Let’s use it productively.

 

Follow Otello Stampacchia on Twitter: @OtelloVC

This article expresses the personal views and perspectives of the author. The views and perspectives expressed here do not necessarily represent the views or perspectives of Omega Fund Management, LLC or any officer, director, partner, member, manager or employee of Omega Fund Management, LLC or any of its affiliated entities.